Cargando…
Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes
Invariant natural killer T (iNKT) cells are a unique T lymphocyte population expressing semi-invariant T cell receptors (TCRs) that recognise lipid antigens presented by CD1d. iNKT cells exhibit potent anti-tumour activity through direct killing mechanisms and indirectly through triggering the activ...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154573/ https://www.ncbi.nlm.nih.gov/pubmed/37153585 http://dx.doi.org/10.3389/fimmu.2023.1176724 |
_version_ | 1785036153899974656 |
---|---|
author | Look, Alex Burns, Daniel Tews, Ivo Roghanian, Ali Mansour, Salah |
author_facet | Look, Alex Burns, Daniel Tews, Ivo Roghanian, Ali Mansour, Salah |
author_sort | Look, Alex |
collection | PubMed |
description | Invariant natural killer T (iNKT) cells are a unique T lymphocyte population expressing semi-invariant T cell receptors (TCRs) that recognise lipid antigens presented by CD1d. iNKT cells exhibit potent anti-tumour activity through direct killing mechanisms and indirectly through triggering the activation of other anti-tumour immune cells. Because of their ability to induce potent anti-tumour responses, particularly when activated by the strong iNKT agonist αGalCer, they have been the subject of intense research to harness iNKT cell-targeted immunotherapies for cancer treatment. However, despite potent anti-tumour efficacy in pre-clinical models, the translation of iNKT cell immunotherapy into human cancer patients has been less successful. This review provides an overview of iNKT cell biology and why they are of interest within the context of cancer immunology. We focus on the iNKT anti-tumour response, the seminal studies that first reported iNKT cytotoxicity, their anti-tumour mechanisms, and the various described subsets within the iNKT cell repertoire. Finally, we discuss several barriers to the successful utilisation of iNKT cells in human cancer immunotherapy, what is required for a better understanding of human iNKT cells, and the future perspectives facilitating their exploitation for improved clinical outcomes. |
format | Online Article Text |
id | pubmed-10154573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101545732023-05-04 Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes Look, Alex Burns, Daniel Tews, Ivo Roghanian, Ali Mansour, Salah Front Immunol Immunology Invariant natural killer T (iNKT) cells are a unique T lymphocyte population expressing semi-invariant T cell receptors (TCRs) that recognise lipid antigens presented by CD1d. iNKT cells exhibit potent anti-tumour activity through direct killing mechanisms and indirectly through triggering the activation of other anti-tumour immune cells. Because of their ability to induce potent anti-tumour responses, particularly when activated by the strong iNKT agonist αGalCer, they have been the subject of intense research to harness iNKT cell-targeted immunotherapies for cancer treatment. However, despite potent anti-tumour efficacy in pre-clinical models, the translation of iNKT cell immunotherapy into human cancer patients has been less successful. This review provides an overview of iNKT cell biology and why they are of interest within the context of cancer immunology. We focus on the iNKT anti-tumour response, the seminal studies that first reported iNKT cytotoxicity, their anti-tumour mechanisms, and the various described subsets within the iNKT cell repertoire. Finally, we discuss several barriers to the successful utilisation of iNKT cells in human cancer immunotherapy, what is required for a better understanding of human iNKT cells, and the future perspectives facilitating their exploitation for improved clinical outcomes. Frontiers Media S.A. 2023-04-19 /pmc/articles/PMC10154573/ /pubmed/37153585 http://dx.doi.org/10.3389/fimmu.2023.1176724 Text en Copyright © 2023 Look, Burns, Tews, Roghanian and Mansour https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Look, Alex Burns, Daniel Tews, Ivo Roghanian, Ali Mansour, Salah Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes |
title | Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes |
title_full | Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes |
title_fullStr | Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes |
title_full_unstemmed | Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes |
title_short | Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes |
title_sort | towards a better understanding of human inkt cell subpopulations for improved clinical outcomes |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154573/ https://www.ncbi.nlm.nih.gov/pubmed/37153585 http://dx.doi.org/10.3389/fimmu.2023.1176724 |
work_keys_str_mv | AT lookalex towardsabetterunderstandingofhumaninktcellsubpopulationsforimprovedclinicaloutcomes AT burnsdaniel towardsabetterunderstandingofhumaninktcellsubpopulationsforimprovedclinicaloutcomes AT tewsivo towardsabetterunderstandingofhumaninktcellsubpopulationsforimprovedclinicaloutcomes AT roghanianali towardsabetterunderstandingofhumaninktcellsubpopulationsforimprovedclinicaloutcomes AT mansoursalah towardsabetterunderstandingofhumaninktcellsubpopulationsforimprovedclinicaloutcomes |